Archives of Gerontology and Geriatrics Plus, Journal Year: 2024, Volume and Issue: unknown, P. 100108 - 100108
Published: Dec. 1, 2024
Language: Английский
Frontiers in Neuroscience, Journal Year: 2023, Volume and Issue: 17
Published: Sept. 5, 2023
Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) affect up to 97% of AD patients, with an estimated 80% current patients experiencing these symptoms. Common AD-associated NPS include depression, anxiety, agitation, aggression, and apathy. The severity is typically linked the disease's progression extent cognitive decline. Additionally, are responsible for a significant increase morbidity, mortality, caregiver burden, earlier nursing home placement, greater healthcare expenditure. Despite their high prevalence impact, there notable lack clinical research on AD. In this article, we explore analyze prevalence, symptom manifestations, challenges diagnosis, treatment options associated Our literature review reveals that distinguishing accurately diagnosing remains challenging task settings. It often difficult discern whether secondary pathophysiological changes from or comorbid psychiatric conditions. Furthermore, availability effective pharmaceutical interventions, as well non-pharmacotherapies AD, limited. By highlighting advance diagnosis NPS, aspire offer new insights into complexity identifying treating within context contribute deeper understanding multifaceted nature
Language: Английский
Citations
43
Psychiatry Research, Journal Year: 2024, Volume and Issue: 340, P. 116114 - 116114
Published: July 31, 2024
Depression and dementia represent significant health challenges in older adults. Despite guidelines recommending antidepressants, their efficacy depressed patients with remains undetermined.
Language: Английский
Citations
4
Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)
Published: Oct. 21, 2024
Language: Английский
Citations
2
CNS Drugs, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 2, 2024
Language: Английский
Citations
2
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Nov. 8, 2023
A series of clinical trials support the effectiveness monoclonal antibodies for generalized myasthenia gravis (MG) compared to placebo, but priority among drugs remains unclear. Therefore, we conduct a frequentist network meta-analysis (NMA) compare relative effects different MG. PubMed, Embase, Cochrane Library, and clinicaltrials.gov were systematically searched eligible studies up 1 June 2023. The primary outcome was efficacy (Myasthenia Gravis Activities Daily Living [MG-ADL] score Quantitative Myasthenia [QMG] score) safety (adverse events [AEs]). Mean difference (MD) risk ratio (RR) with their 95% credible intervals (95%CrIs) used show effect size continuous categorical variables, respectively. quality evidence assessed using Grading Recommendations Assessment, Development Evaluation (GRADE) approach. Thirteen involving 1167 individuals identified NMA. For outcomes, belimumab, efgartigimod, mezagitamab 600mg, nipocalimab 60mg/kg inferior rozanolixzumab 7mg/kg (MD ranged from 2 3.69) 10mg/kg 2.04 3.72) in MG-ADL score, had highest rank probability (83%) according subjective surface under curve ranking area (SUCRA). QMG batoclimab 340mg 4.32 8.52) 680mg 4.11 9.31) more effective than placebo other except rozanolixzumab, SUCRA value (93% 97% respectively). belimumab achieved (89.8%) significant statistical (RR 0.08, 95%CrI 0.01 0.94) 0.86). While all superior might be most However, associated higher incidence AEs. Given limitations inherent indirect comparisons, further head-to-head extensive observational are necessary confirm our findings. https://inplasy.com/?s=202370112, identifier 202370112.
Language: Английский
Citations
4
American Journal of Geriatric Psychiatry, Journal Year: 2024, Volume and Issue: 33(3), P. 322 - 329
Published: Nov. 19, 2024
Language: Английский
Citations
1
Published: Jan. 1, 2024
Background: Depression and dementia represent significant health challenges in older adults, affecting both quality of life independence, with a combined point prevalence 35%. Despite guidelines recommending antidepressants, their efficacy depressed patients remains controversial.Objective: This review primarily aims to determine the effect any-type antidepressant on level depression adults secondly if there is an antidepressants cognitive state, life, functionality old-age population dementia.Methods: A systematic meta-analysis was conducted RCTs, Medline, Embase, Cochrane Central Register Controlled Trials databases. Study participants were aged 65 older, diagnosed any type dementia, excluding those other severe psychiatric conditions or undergoing brain stimulation treatments. We used Risk-of-Bias tool GRADE framework for certainty evidence. Analysis involved standardized mean difference heterogeneous measures, 95% confidence intervals (CIs).Findings: Of 27,771 screened articles, 14 studies, totaling 1909 participants, mild treatment SSRI, SSNRI, atypical, tricyclic included. Due missing information, only 8 studies included quantitative synthesis, 617 participants. No evidence found (SMD -0.10 [-0.26, 0.07]), nor when subgrouped based severity level, secondary outcomes.Interpretation: did not find clinical treating dementia. Methodological might contribute this finding. Funding: specific funding received project. The authors supported by employment at respective institutions.Declaration Interest: All declare that they have no conflicts interest.
Language: Английский
Citations
0
Springer eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 361 - 378
Published: Jan. 1, 2024
Language: Английский
Citations
0
Published: Jan. 1, 2024
Agitation is shared across all stages of dementia but more prevalent in the later stage. It complicates care and nursing people with increases risk harming themselves others. Many studies have examined evidence for managing agitation dementia. However, results are not always consistent, which might be explained by variations definition type presence comorbidities, including other BPSD. The Dementia Working Group International Psychogeriatric Association (IPA) has recently updated criteria defining cognitive disorders proposed an management algorithm that only integrates both pharmacological nonpharmacological interventions also distinguishes strategies different types based on latest available (Sano et al. Int Psychogeriatr:1–13, 2021; Cummings Psychogeriatr, 6:1–12, 2023). References made to these recommendations when describing assessment aggression latter part this chapter.
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11338 - 11338
Published: Oct. 22, 2024
Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic humanistic burdens. It associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, psychosis. NPSs are common in patients AD, affecting up 97% of individuals diagnosed AD. The severity NPS linked progression cognitive decline. leads increased morbidity, mortality, caregiver burden, earlier nursing home placement, higher healthcare costs. Despite their impact, clinical research on AD limited. In settings, accurately distinguishing diagnosing related remains challenge. Additionally, conventional treatments for often ineffective, highlighting the need new therapies target these specific symptoms. Understanding comorbidities can aid early diagnosis better management this review, we provide summary neurological psychiatric candidates under development treatment based therapeutic targets mechanisms. On top studied so far, review adds recent advancements understanding social functional impairment This also provides information contribute advancement studies translational field by emphasizing mechanisms action focused AD-related rather than targeted drug development. Above all, considering relative lack despite importance clinical, medical, research, it may increase interest its pathophysiological mechanisms, potential molecules antioxidant potential.
Language: Английский
Citations
0